![]() |
|
|
Vol. 281, Issue 3, 1317-1329, 1997
Clinical Pharmaceutical Scientist Program, Departments of Pharmacy
and Therapeutics (R.J.B., F.S.S.) and
Pharmaceutical Sciences (P.D.K.),
School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania;
Departments of
Medicine (F.J.K.) and
Pharmacology (I.J.R.), School of
Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;
Clinical
Pharmacokinetics, The Upjohn Company, Kalamazoo, Michigan (C.E.W.); and
Novum Inc., Pharmaceutical Research Services, Pittsburgh, Pennsylvania
(R.B.S.)
This study was designed to determine whether age influences sensitivity
to alprazolam and/or rate of acute tolerance development to the effects
of alprazolam. Three treatments were each separated by 4 weeks.
Twenty-five young (ages 22- 35) and 13 elderly (ages 65-75) men
received 2 mg of alprazolam/2 min i.v. Blood samples were obtained over
48 hr, and sedative, psychomotor and memory effects were assessed
serially for 12 hr. Clearance was lower (P = .05) and elimination
t[1/2] was longer (P = .005) in the
elderly, but area under the concentration curve to 12 hr and maximum
concentration did not differ by age group. Maximum impairment was
greater in the elderly for all assessments. Mean EC50
values differed between the elderly (25.3 and 25.0 ng/ml) and the young
(39.8 and 36.5 ng/ml) on card sorting and digit symbol substitution,
respectively (P < .001). Bolus treatment data were used to
individualize doses for the crossover of placebo and alprazolam;
infusions were designed to maintain a plateau alprazolam concentration
between 1 and 9 hr. Alprazolam concentrations through 12 hr did not
differ between the young and elderly. Median t[1/2] for offset of effect for digit
symbol substitution was 2.8 hr in the young and 4.9 hr in the elderly
(P = .05). Therefore, aging decreases alprazolam clearance and
increases sensitivity to effects of alprazolam through a mechanism
other than pharmacokinetics; aging also decreases the rate of offset of
effect of alprazolam. In addition, the data provide insight into the
intensity of initial effect as a determinant of rate of tolerance
development.
This article has been cited by other articles:
![]() |
K. C. Patki, L. L. von Moltke, J. S. Harmatz, L. M. Hesse, M. H. Court, and D. J. Greenblatt Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 874 - 879. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Warrington, J. W. Poku, L. L. von Moltke, R. I. Shader, J. S. Harmatz, and D. J. Greenblatt Effects of Age on In Vitro Midazolam Biotransformation in Male CD-1 Mouse Liver Microsomes J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1024 - 1031. [Abstract] [Full Text] |
||||